Notably, a considerable subset of oral squamous cell carcinoma (OSCC) patients have comorbidities, with type 2 diabetes mellitus (T2DM) being a prevalent one. Prevalence of diabetes at the country level was estimated to be 7.3% and 7.7% in year 2017 and in year 2016 respectively using national population-based studies on people aged more than or equal to 20 years’ obtained from ICMR-INDIAB multi-center study [6]. This comorbidity can considerably exacerbate inflammation due to the insufficiency of insulin action, further complicating the disease course [7]. This evidence concerns the gene INS and type 2 diabetes mellitus.